Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study.

Haematologica·2024
Same author

International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.

The Lancet. Oncology·2024
Same author

Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.

Cancer medicine·2023
Same author

CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?

Haematologica·2023
Same author

Response to Caravita di Toritto and Rago.

European journal of haematology·2022
Same author

Conditioning with melphalan 200 mg/m<sup>2</sup> and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care.

European journal of haematology·2022

Related Experiment Video

Updated: Jun 11, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Progress in allogeneic transplantation for multiple myeloma.

Gösta Gahrton1

  • 1Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. gosta.gahrton@ki.se

European Journal of Haematology
|July 9, 2010
PubMed
Summary

Allogeneic stem cell transplants for multiple myeloma evolved from myeloablative to reduced intensity conditioning (RIC). RIC reduces mortality but has higher relapse rates, though survival may improve compared to autologous transplants.

More Related Videos

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

Related Experiment Videos

Last Updated: Jun 11, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Medicine

Background:

  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been explored for multiple myeloma since the 1980s.
  • Early myeloablative conditioning regimens (TBI + cyclophosphamide) showed low relapse but high mortality, limiting widespread use.
  • Reduced intensity conditioning (RIC) non-myeloablative allo-HSCT significantly lowers transplant-related mortality compared to myeloablative approaches.

Purpose of the Study:

  • To review the evolution and efficacy of allogeneic stem cell transplantation for multiple myeloma.
  • To compare outcomes of myeloablative versus reduced intensity conditioning (RIC) regimens.
  • To explore potential future improvements in allo-HSCT for multiple myeloma.

Main Methods:

  • Historical review of conditioning regimens in allo-HSCT for multiple myeloma.
  • Comparison of myeloablative conditioning with reduced intensity conditioning (RIC) based on published data.
  • Analysis of outcomes including transplant-related mortality, relapse/progression rates, progression-free survival, and overall survival.

Main Results:

  • Myeloablative conditioning resulted in low relapse but high transplant-related mortality, with no clear survival benefit.
  • RIC regimens significantly reduced transplant-related mortality compared to myeloablative conditioning.
  • Tandem autologous/RIC allogeneic transplantation showed improved progression-free and overall survival compared to autotransplantation in some trials, despite higher treatment-related mortality than autologous alone.

Conclusions:

  • While myeloablative allo-HSCT is largely abandoned for multiple myeloma due to toxicity, RIC offers a safer alternative with potentially improved survival outcomes.
  • Further research incorporating novel agents (bortezomib, immunomodulatory drugs) and cellular therapies (NK cells) may enhance the efficacy of allo-HSCT.
  • Specific patient risk groups might still benefit from myeloablative allo-HSCT, and occasional cures are possible.